Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4

Pharmaceutical Research

Volumn 23, Issue 12, 2006, Pages 2691-2708

  Lau, Wei C ^a,c   Gurbel, Paul A ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^c UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

Antiplatelet resistant; Antiplatelet therapy; Aspirin; Clopidogrel; Platelet

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CELECOXIB; CLOPIDOGREL; COLLAGEN; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450 3A4; ERYTHROMYCIN; FIBRINOGEN RECEPTOR ANTAGONIST; GALLIC ACID PROPYL ESTER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; IBUPROFEN; KIRA; NONSTEROID ANTIINFLAMMATORY AGENT; PRASUGREL; PRAVASTATIN; PRODRUG; PYRIDINE DERIVATIVE; RIFAMPICIN; ROFECOXIB; STATINE DERIVATIVE; TROLEANDOMYCIN; UNINDEXED DRUG; VALDECOXIB;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPETITIVE INHIBITION; CORONARY STENT; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME INDUCTION; GASTROINTESTINAL TOXICITY; GENETIC VARIABILITY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; IMPLANTATION; LOADING DRUG DOSE; LOW DRUG DOSE; METABOLIC ACTIVATION; MORTALITY; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENT DISEASE; RELIABILITY; REPEATED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; STROKE; SYSTEMATIC REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA; THROMBOSIS;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; ASPIRIN; DRUG INTERACTIONS; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 33845372276     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-9084-4     Document Type: Review

References (133)

1. P. A. Gurbel, K. P. Bliden, and K. M. Hayes et al. Platelet activation in myocardial ischemic syndromes. Expert Rev. Cardiovasc. Ther 2:535-545 (2004).
2. A. P. Selwyn. Prothrombotic and antithrombotic pathways in acute coronary syndromes. Am. J. Cardiol. 91:3H-11H (2003).
3. K. H. Mak, G. Belli, and S. G. Ellis et al. Subacute stent thrombosis: evolving issues and current concepts. J. Am. Coll. Cardiol. 27:494-503 (1996).
4. A. Budaj, S. Yusuf, and S. R. Mehta et al. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation 106:1622-1626 (2002).
5. S. Yusuf, F. Zhao, and S. R. Mehta et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345:494-502 (2001).
6. D. L. Bhatt, M. E. Bertrand, and P. B. Berger et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J. Am. Coll. Cardiol. 39:9-14 (2002).
7. Antiplatelet Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71-86 (2002).
8. B. Rocca and C. Patrono. Determinants of the interindividual variability in response to antiplatelet drugs. J. Thromb. Haemost. 3:1597-1602 (2005).
9. S. R. Steinhubl, R. Charnigo, and D. J. Moliterno. Resistance to antiplatelet resistance is it justified?. J. Am. Coll. Cardiol. 45:1757-1758 (2005).
10. C. P. Martin and R. L. Talbert. Aspirin resistance: an evaluation of current evidence and measurement methods. Pharmacotherapy 25:942-953 (2005).
11. T. A. Nguyen, J. G. Diodati, and C. Pharand. Resistance to clopidogrel: a review of the evidence. J. Am. Coll. Cardiol. 45:1157-1164 (2005).
12. B. Stein, V. Fuster, and D. H. Israel et al. Platelet inhibitor agents in cardiovascular disease: an update. J. Am. Coll. Cardiol. 14:813-836 (1989).
13. A. I. Schafer. Antiplatelet therapy. Am. J. Med. 101:199-209 (1996).
14. T. Nakamura, J. Kambayashi, and M. Okuma et al. Activation of the GP IIb-IIIa complex induced by platelet adhesion to collagen is mediated by both alpha2beta1 integrin and GP VI. J. Biol. Chem. 274:11897-11903 (1999).
15. A. Schafer, N. M. Ali, and G. N. Levine. Hemostasis, thrombosis, fibrinolysis, and cardiovascular disease. In E. Braunwald, D. P. Zipes, and P. Libby. (eds.), 6th ed., Saunders, Philadelphia, 2001, pp. 2099-2132.
16. R. J. Shebuski and K. S. Kilgore. Role of inflammatory mediators in thrombogenesis. J. Pharmacol. Exp. Ther. 300:729-735 (2002).
17. H. Loppnow, R. Bil, and S. Hirt et al. Platelet-derived interleukin-1 induces cytokine production, but not proliferation of human vascular smooth muscle cells. Blood 91:134-141 (1998).
18. F. Marti, E. Bertran, and M. Llucia et al. Platelet factor 4 induces human natural killer cells to synthesize and release interleukin-8. J. Leukoc. Biol. 72:590-597 (2002).
19. P. Patrignani, P. Filabozzi, and C. Patrono. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J. Clin. Invest. 69:1366-1372 (1982).
20. W. M. Samara, K. P. Bliden, and U. S. Tantry et al. The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thromb. Res. 115:89-94 (2005).
21. P. A. Gurbel, K. P. Bliden, and K. M. Hayes et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J. Am. Coll. Cardiol. 45:1392-1396 (2005).
22. P. A. Gurbel, W. M. Samara, and K. P. Bliden. Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis. Platelets 15:95-99 (2004).
23. N. S. Nicholson, S. G. Panzer-Knodle, and N. F. Haas et al. Assessment of platelet function assays. Am. Heart J. 135:S170-S178 (1998).
24. M. E. McKenzie, P. A. Gurbel, and D. J. Levine et al. Clinical utility of available methods for determining platelet function. Cardiology 92:240-247 (1999).
25. E. F. Mammen, R. S. Alshameeri, and P. C. Comp. Preliminary data from a field trial of the PFA-100 system. Semin. Thromb. Hemost. 21(Suppl 2):113-121 (1995).
26. E. F. Mammen, P. C. Comp, and R. Gosselin et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin. Thromb. Hemost. 24:195-202 (1998).
27. K. Kottke-Marchant, J. B. Powers, and L. Brooks et al. The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100). Clin. Appl. Thromb. Hemost. 5:122-130 (1999).
28. B. S. Coller, D. Lang, and L. E. Scudder. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade. Circulation 95:860-867 (1997).
29. R. M. Craft, J. J. Chavez, and C. C. Snider et al. Comparison of modified Thrombelastograph and Plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients. J. Lab. Clin. Med. 145:309-315 (2005).
30. U. S. Tantry, K. P. Bliden, and P. A. Gurbel. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J. Am. Coll. Cardiol. 46:1705-1709 (2005).
31. J. W. Eikelboom, J. Hirsh, and J. I. Weitz et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105:1650-1655 (2002).
32. M. J. McQueen, E. Lonn, and H. C. Gerstein et al. The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences. Scand J. Clin. Lab. Invest. Suppl. 240:143-156 (2005).
33. M. Cattaneo. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler. Thromb. Vasc. Biol. 24:1980-1987 (2004).
34. P. A. Gum, K. Kottke-Marchant, and P. A. Welsh et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J. Am. Coll. Cardiol. 41:961-965 (2003).
35. W. H. Chen, P. Y. Lee, and W. Ng et al. Aspirin resistance is associated with a high incidence of myonecrosis after nonurgent percutaneous coronary intervention despite clopidogrel pretreatment. J. Am. Coll. Cardiol. 43:1122-1126 (2004).
36. K. Grundmann, K. Jaschonek, and B. Kleine et al. Aspirin nonresponder status in patients with recurrent cerebral ischemic attacks. J. Neurol. 250:63-66 (2003).
37. A. D. Michelson, M. Cattaneo, and J. W. Eikelboom et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J. Thromb. Haemost. 3:1309-1311 (2005).
38. K. H. Grotemeyer, H. W. Scharafinski, and I. W. Husstedt. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb. Res. 71:397-403 (1993).
39. J. C. Wang, D. Aucoin-Barry, and D. Manuelian et al. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay - ASA. Am. J. Cardiol. 92:1492-1494 (2003).
40. K. Andersen, M. Hurlen, and H. Arnesen et al. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb. Res. 108:37-42 (2002).
41. K. A. Schwartz, D. E. Schwartz, and K. Ghosheh et al. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am. J. Cardiol. 95:973-975 (2005).
42. A. Bruno, J. P. McConnell, and S. N. Cohen et al. Serial urinary 11-dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction. Stroke 35:727-730 (2004).
43. F. Cipollone, G. Ciabattoni, and P. Patrignani et al. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 102:1007-1013 (2000).
44. J. A. Cambria-Kiely and P. J. Gandhi. Possible mechanisms of aspirin resistance. J. Thromb. Thrombolysis 13:49-56 (2002).
45. J. A. Cambria-Kiely and P. J. Gandhi. Aspirin resistance and genetic polymorphisms. J. Thromb. Thrombolysis 14:51-58 (2002).
46. M. K. Halushka, L. P. Walker, and P. V. Halushka. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin. Pharmacol. Ther. 73:122-130 (2003).
47. E. Ferrari, M. Benhamou, and P. Cerboni et al. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J. Am. Coll. Cardiol. 45:456-459 (2005).
48. M. Stillings, I. Havlik, and M. Chetty et al. Comparison of the pharmacokinetic profiles of soluble aspirin and solid paracetamol tablets in fed and fasted volunteers. Curr. Med. Res. Opin. 16:115-124 (2000).
49. P. J. Mason, A. K. Jacobs, and J. E. Freedman. Aspirin resistance and atherothrombotic disease. J. Am. Coll. Cardiol. 46:986-993 (2005).
50. M. Hurlen, I. Seljeflot, and H. Arnesen. Increased platelet aggregability during exercise in patients with previous myocardial infarction. Lack of inhibition by aspirin. Thromb. Res. 99:487-494 (2000).
51. T. Kawasaki, Y. Ozeki, and T. Igawa et al. Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke 31:591-595 (2000).
52. E. H. Awtry and J. Loscalzo. Aspirin. Circulation 101:1206-1218 (2000).
53. F. Catella-Lawson, M. P. Reilly, and S. C. Kapoor et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. 345:1809-1817 (2001).
54. T. Kurth, R. J. Glynn, and A. M. Walker et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 108:1191-1195 (2003).
55. T. M. MacDonald and L. Wei. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361:573-574 (2003).
56. S. E. Kimmel, J. A. Berlin, and M. Reilly et al. The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J. Am. Coll. Cardiol. 43:985-990 (2004).
57. D. Mukherjee, S. E. Nissen, and E. J. Topol. Risk of cardiovascular events associated with selective COX-2 inhibitors. Jama 286:954-959 (2001).
58. D. Mukherjee, S. E. Nissen, and E. J. Topol. Cox-2 inhibitors and cardiovascular risk: we defend our data and suggest caution. Clevel. Clin. J. Med. 68:963-964 (2001).
59. P. J. Newman, R. S. Derbes, and R. H. Aster. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J. Clin. Invest. 83:1778-1781 (1989).
60. A. D. Michelson, M. I. Furman, and P. Goldschmidt-Clermont et al. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation 101:1013-1018 (2000).
61. A. H. Goodall, N. Curzen, and M. Panesar et al. Increased binding of fibrinogen to glycoprotein IIIa-proline33 (HPA-1b, PlA2, Zwb) positive platelets in patients with cardiovascular disease. Eur. Heart J. 20:742-747 (1999).
62. D. Burr, H. Doss, and G. E. Cooke et al. A meta-analysis of studies on the association of the platelet PlA polymorphism of glycoprotein IIIa and risk of coronary heart disease. Stat. Med. 22:1741-1760 (2003).
63. A. Undas, K. Brummel, and J. Musial et al. Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 104:2666-2672 (2001).
64. F. Cipollone, B. Rocca, and C. Patrono. Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler. Thromb. Vasc. Biol. 24:246-255 (2004).
65. J. Maclouf, G. Folco, and C. Patrono. Eicosanoids and isoeicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease. Thromb. Haemost. 79:691-705 (1998).
66. W. C. Lau, L. A. Waskell, and P. B. Watkins et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107:32-37 (2003).
67. P. Savi, J. M. Pereillo, and M. F. Uzabiaga et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb. Haemost. 84:891-896 (2000).
68. R. T. Dorsam and S. P. Kunapuli. Central role of the P2Y12 receptor in platelet activation. J. Clin. Invest. 113:340-345 (2004).
69. J. A. Remijn, Y. P. Wu, and E. H. Jeninga et al. Role of ADP receptor P2Y(12) in platelet adhesion and thrombus formation in flowing blood. Arterioscler. Thromb. Vasc. Biol. 22:686-691 (2002).
70. C. Leon, M. Alex, and A. Klocke et al. Platelet ADP receptors contribute to the initiation of intravascular coagulation. Blood 103:594-600 (2004).
71. M. Gawaz. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc. Res. 61:498-511 (2004).
72. E. F. Plow and T. Byzova. The biology of glycoprotein IIb-IIIa. Coron. Artery Dis. 10:547-551 (1999).
73. M. G. Rolf, C. A. Brearley, and M. P. Mahaut-Smith. Platelet shape change evoked by selective activation of P2X1 purinoceptors with alpha,beta-methylene ATP. Thromb. Haemost. 85:303-308 (2001).
74. C. Vial, S. J. Pitt, and J. Roberts et al. Lack of evidence for functional ADP-activated human P2X1 receptors supports a role for ATP during hemostasis and thrombosis. Blood 102:3646- 3651 (2003).
75. C. Oury, M. J. Kuijpers, and E. Toth-Zsamboki et al. Overexpression of the platelet P2X1 ion channel in transgenic mice generates a novel prothrombotic phenotype. Blood 101:3969-3976 (2003).
76. P. B. Conley and S. M. Delaney. Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis. Curr. Opin. Hematol. 10:333-338 (2003).
77. P. A. Gurbel, W. C. Lau, and K. P. Bliden et al. Clopidogrel resistance: implications for coronary stenting. Curr. Pharm. Des. 12:1261-1269 (2006).
78. D. Woulfe, H. Jiang, and R. Mortensen et al. Activation of Rap1B by G(i) family members in platelets. J. Biol. Chem. 277:23382-23390 (2002).
79. P. Lova, S. Paganini, and F. Sinigaglia et al. A Gi-dependent pathway is required for activation of the small GTPase Rap1B in human platelets. J. Biol. Chem. 277:12009-12015 (2002).
80. J. Geiger, J. Brich, and P. Honig-Liedl et al. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler. Thromb. Vasc. Biol. 19:2007-2011 (1999).
81. P. Barragan, J. L. Bouvier, and P. O. Roquebert et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter. Cardiovasc. Interv. 59:295-302 (2003).
82. S. R. Steinhubl, P. B. Berger, and J. T. Mann et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288:2411-2420 (2002).
83. I. Muller, F. Besta, and C. Schulz et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb. Haemost. 89:783-787 (2003).
84. P. A. Gurbel, C. C. Cummings, and C. R. Bell et al. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Am. Heart J. 145:239-247 (2003).
85. D. E. Cutlip, D. S. Baim, and K. K. Ho et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 103:1967-1971 (2001).
86. P. A. Gurbel, K. P. Bliden, and B. L. Hiatt et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107:2908-2913 (2003).
87. D. R. Nelson, L. Koymans, and T. Kamataki et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42 (1996).
88. P. Savi, J. Combalbert, and C. Gaich et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb. Haemost. 72:313-317 (1994).
89. M. Hasegawa, A. Sugidachi, and T. Ogawa et al. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor. Thromb. Haemost. 94:593-598 (2005).
90. M. Kazui, T. Ishizuka, N. Yamamura, et al. Mechanism of production of pharmacologically active metabolites of CS-747, a new pro-drug ADP-receptor antagonist. Thromb. Haemost. (sup):P1916 (2001).
91. W. C. Lau, L. A. Waskell, and D. Carville et al. The antiplatelet activity of clopidogrel is inhibited by atorvastatin but not by pravastatin. Circulation 102:abstract (2000).
92. W. Jacobsen, B. Kuhn, and A. Soldner et al. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab. Dispos. 28:1369-1378 (2000).
93. T. A. Clarke and L. A. Waskell. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab. Dispos. 31:53-59 (2003).
94. W. C. Lau, L. A. Waskell, and P. Watkins et al. The effect of drugs which are known inducers and inhibitors of human cytochrome P450 3A on the platelet inhibitory activity of clopidogrel. J. Am. Coll. Cardiol. 39: (2002).
95. C. Handschin and U. A. Meyer. Induction of drug metabolism: the role of nuclear receptors. Pharmacol. Rev. 55:649-673 (2003).
96. H. M. Bolt. Rifampicin, a keystone inducer of drug metabolism: from Herbert Remmer's pioneering ideas to modern concepts. Drug Metab. Rev. 36:497-509 (2004).
97. J. M. Rae, M. D. Johnson, and M. E. Lippman et al. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J. Pharmacol. Exp. Ther. 299:849-857 (2001).
98. B. Goodwin, E. Hodgson, and C. Liddle. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol. 56:1329-1339 (1999).
99. W. C. Lau, P. A. Gurbel, and P. B. Watkins et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 109:166-171 (2004).
100. S. D. Wiviott and E. M Antman. Clopidogrel resistance: a new chapter in a fast-moving story. Circulation 109:3064-3067 (2004).
101. P. A. Gurbel, K. P. Bliden, and W. Samara et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J. Am. Coll. Cardiol. 46:1827-1832 (2005).
102. S. Matetzky, B. Shenkman, and V. Guetta et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109:3171-3175 (2004).
103. P. A. Gurbel, A. I. Malinin, and K. P. Callahan et al. Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation. Am. J. Cardiol. 90:312-315 (2002).
104. J. E. Mobley, S. J. Bresee, and D. C. Wortham et al. Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am. J. Cardiol. 93:456-458 (2004).
105. P. A. Gurbel and K. P. Bliden. A new method of representing drug-induced platelet inhibition: better description of time course, response variability, non-response, and heightened activity. Platelets 14:481-483 (2003).
106. P. Jaremo, T. L. Lindahl, and S. G. Fransson et al. Individual variations of platelet inhibition after loading doses of clopidogrel. J. Intern. Med. 252:233-238 (2002).
107. P. A. Gurbel and K. P. Bliden. Durability of platelet inhibition by clopidogrel. Am. J. Cardiol. 91:1123-1125 (2003).
108. Y. Uno, Y. Sakamoto, and K. Yoshida et al. Characterization of six base pair deletion in the putative HNF1-binding site of human PXR promoter. J. Hum. Genet. 48:594-597 (2003).
109. W. C. Lau. St. John's wort enhances the platelet inhibitory effect of clopidogrel in clopidogrel "Resistant" healthy volunteers. J. Am. Coll. Cardiol. 45:Abstract (2005).
110. I. Muller, M. Seyfarth, and S. Rudiger et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 85:92-93 (2001).
111. A. Kastrati, J. Mehilli, and H. Schuhlen et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N. Engl. J. Med. 350:232-238 (2004).
112. W. C. Lau, J. M. Rae, P. F. Hollenberg et al. Clopidogrel is an inducer and a potent reversible inhibitor of cytochrome P450 3A4 in vitro. J. Am. Coll. Cardiol. 43:493A (2004).
113. J. Saw, S. R. Steinhubl, and P. B. Berger et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 108:921-924 (2003).
114. V. L. Serebruany, M. G. Midei, and A. I. Malinin et al. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch. Intern. Med. 164:2051-2057 (2004).
115. H. Wienbergen, A. K. Gitt, and R. Schiele et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am. J. Cardiol. 92:285-288 (2003).
116. J. Brophy, V. Costa, and M. Babapulle. A pharmaco-epidemiological study of the interaction between atorvastatin and clopidogrel following percutaneous coronary interventions. J. Am. Coll. Cardiol. 43:50A Abstract (2004).
117. M. Blumenthal (ed.), The complete German Commission E monographs-therapeutic guide to herbal medicines. American Botanical Council, 1998.
118. R. E. Watkins, J. M. Maglich, and L. B. Moore et al. 2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin. Biochemistry 42:1430-1438 (2003).
119. L. B. Moore, B. Goodwin, and S. A. Jones et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl. Acad. Sci. USA. 97:7500-7502 (2000).
120. A. Biber, H. Fischer, and A. Romer et al. Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers. Pharmacopsychiatry 31(Suppl 1):36-43 (1998).
121. C. A. Roby, G. D. Anderson, and E. Kantor et al. St John's Wort: effect on CYP3A4 activity. Clin. Pharmacol. Ther. 67:451-457 (2000).
122. J. McEwen, G. Strauch, and P. Perles et al. Clopidogrel bioavailability: absence of influence of food or antacids. Semin. Thromb. Hemost. 25(Suppl 2):47-50 (1999).
123. N. Beckerath von, D. Taubert, and G. Pogatsa-Murray et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial. Circulation 112:2946-2950 (2005).
124. D. Taubert, A. Kastrati, and S. Harlfinger et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb. Haemost. 92:311-316 (2004).
125. E. Wang, C. N. Casciano, and R. P. Clement et al. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm. Res. 18:800-806 (2001).
126. K. Bogman, A. K. Peyer, and M. Torok et al. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br. J. Pharmacol. 132:1183-1192 (2001).
127. T. Sakaeda, K. Takara, and M. Kakumoto et al. Simvastatin and lovastatin, but not pravastatin, interact with MDR1. J. Pharm. Pharmacol. 54:419-423 (2002).
128. P. Fontana, A. Dupont, and S. Gandrille et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 108:989-995 (2003).
129. D. J. Angiolillo, A. Fernandez-Ortiz, and E. Bernardo et al. Lack of association between the P2Y(12) receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb. Res. 116:491-497 (2005).
130. A. Sugidachi, F. Asai, and T. Ogawa et al. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br. J. Pharmacol. 129:1439-1446 (2000).
131. Y. Niitsu, J. A. Jakubowski, and A. Sugidachi et al. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin. Thromb. Hemost. 31:184-194 (2005).
132. S. D. Wiviott, E. M. Antman, and K. J. Winters et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the joint utilization of medications to block platelets optimally (JUMBO)-TIMI 26 trial. Circulation 111:3366-3373 (2005).
133. F. Storey. The P2Y12 receptor as a therapeutic target in cardiovascular disease. Platelets 12:197-209 (2001).